Also worth revisiting page 9 of the 2014 Annual Report re- Master Switches & Transcription Factors - while yes some time has lapsed it's also worth noting that the majority of the past 5 big pharma deals have all taken 9-12 months to move from early stage discussions to formalised deals with ink to paper - largely I assume the intricacies of each.
Still punting on a deal before end of June. 
"The initial stages of Phylogica’s oncology program will investigate the capacity of peptides in the company’s Phylomer libraries to inhibit the activity of transcription factors – the critical proteins that bind DNA and regulate how genes express themselves in cells to switch biological processes on and off.
While transcription factors are among the most validated targets in cancer, they have generally proven intractable to small molecule drugs. However, mounting evidence suggests that larger biologics – including peptides – can be more effective at inhibiting transcription factors. Phylomer technology has already proven well suited to addressing transcription factor targets, generating impressive hit rates and biological activities in a range of biological assays, including animal models. The proven success of Phylogica in both hitting this target class and delivering Phylomers into cells significantly lowers the risk of this approach.
Several Pharma companies have already expressed an interest in partnering with Phylogica to establish the feasibility of using peptide drugs to modulate high-value transcription factor targets. The ultimate goal of the oncology program will be to fully validate the integration of the company’s drug delivery and drug discovery platforms. This integration provides rich opportunities to develop our Phylomer libraries in conjunction with a dedicated internal or partnered discovery programs."
(20min delay)